0000842023false00008420232026-11-032026-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 3, 2026
BIO-TECHNE CORPORATION
(Exact Name of Registrant as Specified in its Charter)
| | |
Minnesota | 0-17272 | 41-1427402 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
|
614 McKinley Place NE Minneapolis, Minnesota 55413 |
(Address of Principal Executive Offices) (Zip Code) |
|
(612) 379-8854 |
(Registrant’s Telephone Number, Including Area Code) |
|
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report) |
Securities registered pursuant to Section 12(b) of the Act:
| | |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock | TECH | NASDAQ |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
A copy of the press release issued by Bio-Techne Corporation on November 3, 2026, announcing a cash dividend is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits |
| |
99.1 | Press Release, dated November 3, 2026, announcing cash dividend |
| |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIO-TECHNE CORPORATION |
| |
Date: November 3, 2026 | By: | /s/ Shane V. Bohnen |
| Shane V. Bohnen |
| Senior Vice President, General Counsel and Secretary |
BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS, November 3, 2026/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2026. The quarterly dividend will be payable November 23, 2026, to all common shareholders of record at the close of business on November 13, 2026, provided Bio-Techne’s previously announced transaction with Merck KGaA, Darmstadt, Germany has not closed on or before the close of business on November 13, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis, as applicable.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2026 and has approximately 3,000 employees worldwide. For more information on Bio-Techne and its brands, please visit www.biotechne.com.
Forward-Looking Statements
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, including statements regarding the payment and timing of the quarterly dividend and the pending acquisition of Bio-Techne by Merck KGaA, Darmstadt, Germany. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including: the timing of completion of the pending transaction, including whether it is completed on or before the dividend record date; the satisfaction of the conditions to the pending transaction, including receipt of required shareholder and regulatory approvals; the effect of the announcement or pendency of the transaction on Bio-Techne’s business, operations and stock price; and the other factors described under “Risk Factors” in Bio-Techne’s Annual Report on Form 10-K for the fiscal year ended June 30, 2026 and its subsequent Quarterly Reports on Form 10-Q and other filings with the SEC.
For additional information concerning such factors, see the section titled “Risk Factors” in the Company’s annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
| Contact: | David Clair, Vice President, Investor Relations |
David.Clair@bio-techne.com
612-656-4416
